Last reviewed · How we verify
H1N1 vaccination
The H1N1 vaccination developed by the University of Pennsylvania is currently marketed, positioning it as an established player in the influenza vaccine market. A key strength is the protection of its core composition through a patent expiring in 2028, providing a significant period of exclusivity. The primary risk lies in the competitive landscape, where multiple other H1N1 vaccines are also available, potentially impacting market share.
At a glance
| Generic name | H1N1 vaccination |
|---|---|
| Sponsor | University of Pennsylvania |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines
- Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients (PHASE2)
- Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women (PHASE2)
- Cohort Study Evaluating the Clinical Effectiveness, Safety and Immunogenicity to the Pandemic Influenza Vaccination (PHASE4)
- Vaccination Against Influenza in Autoimmune Diseases (PHASE4)
- Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff. (PHASE4)
- A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months (PHASE3)
- Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H1N1 vaccination CI brief — competitive landscape report
- H1N1 vaccination updates RSS · CI watch RSS
- University of Pennsylvania portfolio CI